Subcellular targeting of survivin peptides: A multi-axis approach to cancer therapy
Abstract
Survivin is a highly attractive cancer target because it is strongly overexpressed in many tumors but largely absent in most normal adult tissues, providing relative tumor selectivity.1 As an inhibitor of apoptosis protein (IAP), survivin binds and sequesters the mitochondrial pro-apoptotic factor SMAC/Diablo, which normally neutralizes IAPs such as XIAP, allowing caspase-3 and caspase-9 to drive apoptosis.2,3 By trapping SMAC/Diablo, survivin preserves IAP function, keeps caspases inactive, and supports cancer cell survival.
Fields of Study & Subjects
RNA Interference and Gene Delivery
Nanoparticle-Based Drug Delivery
Cell death mechanisms and regulation
Publication details
- Journal / source
- Molecular Therapy Oncology
- Volume
- 34
- Issue
- 1
- Pages
- 201145–201145
- Publication date
- 17 February 2026
- Language
- EN